The MANCO consortium is developing monoclonal antibodies against 2019-nCoV. CR2O is a partner within this consortium and responsible for the clinical operations. For pre-clinical and clinical Phase I study we require a GMP manufacturing company for the production of monoclonal antibodies (IMP) using the C1 expression system (Myceliophthora thermophila fungus).

The procurement includes the following:

• generate and release master and working cell banks of the relevant C1 line, scale to pilot scale and release under GMP.

• If possible, fill and finish into vials and release testing.